
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. demonstrated impressive financial performance, reporting record total revenues of $12.1 million for the quarter, which reflects a 154% year-over-year increase and surpasses the consensus estimate of $9.9 million. The company's robust growth can be attributed to an increase in the average selling price driven by a higher number of Medicare patients, alongside a 106% year-over-year surge in total revenue units. Furthermore, the positive outlook is supported by management's guidance predicting total revenues of $50-53 million for 2025, coupled with strong operational metrics such as a gross margin increase to 71% and a significant rise in the reimbursement pipeline to 1,389 units.
Bears say
Myomo Inc. reported a decrease in its backlog of insurance-authorized orders, falling from 316 to 272, which raises concerns about future demand and revenue stability. The company faces significant risks, including balance sheet and liquidity challenges, potential failures in product safety and efficacy, issues with regulatory approvals, reimbursement difficulties, and heightened competition, all contributing to a complex risk landscape. Additionally, while a net loss of $0.01 per share was recorded, this was still a slight improvement over the anticipated consensus loss, suggesting ongoing financial difficulties that undermine investor confidence.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares